ライフサイエンスコーパス: dopamine transporter

1 e and expression of tyrosine hydroxylase and dopamine transporter.

2 smitter-sodium symporters, such as the human dopamine transporter.

3 ase (COMT), but negligible expression of the dopamine transporter.

4 still reinforcing even in the absence of the dopamine transporter.

5 ear accumbens without affecting the level of dopamine transporter.

6 ompete with (123)I-FP-CIT for binding to the dopamine transporter.

7 s that could not be reversed by blocking the dopamine transporter.

8 o cholesterol/CHS in Drosophila melanogaster dopamine transporter.

9 n the transport of AMPH into the cell by the dopamine transporter.

10 increases synaptic dopamine by blocking the dopamine transporter.

11 iors by regulating the level and function of dopamine transporters.

12 both total and synaptic membrane-associated dopamine transporters.

13 se of dopamine through reverse activation of dopamine transporters.

14 amics simulations of a complete model of the dopamine transporter, a NSS protein, we observed a parti

15 asurement of functional parameters including dopamine transporter activity and dopamine release at th

16 in this cohort suggests that higher residual dopamine transporter activity is likely to contribute to

17 fficacy was associated with a suppression of dopamine transporter activity, which was reversed during

18 Class II ligands, including the dopamine transporter, adopt a canonical binding mode wit

19 ase (TH), vesicular monoamine transporter 2, dopamine transporter and aldehyde dehydrogenase 1.

20 those in WTs, the striatal protein levels of dopamine transporter and D2 dopamine receptor were incre

21 imarily regulate striatal dopamine function--dopamine transporter and D2 receptors--was significantly

22 in the striatum, as well as altered striatal dopamine transporter and D2, but not D1, receptor densit

23 and to relate findings to juvenile levels of dopamine transporter and D2-like receptor availabilities

24 models based on the Drosophila melanogaster dopamine transporter and docked paroxetine to these mode

25 show that betaPEA, like Amph, activates the dopamine transporter and the amine-gated chloride channe

26 The tetracyclic compound inhibits both the dopamine transporter and the serotonin transporter, and

27 appears to be consistently smaller than the dopamine transporter and vesicular monoamine transporter

28 ulant drug used to treat ADHD), which blocks dopamine transporters and norepinephrine transporters, a

29 the expression of the dopamine D2 receptor, dopamine transporter, and adenosine A1 receptor and decr

30 ne uptake, increases dopamine efflux via the dopamine transporter, and affects the excitability of do

31 re scanned with PET tracers for the membrane dopamine transporter, and dopamine synthesis and storage

32 markers, dopamine, tyrosine hydroxylase, and dopamine transporter are deficient in the ileum of Cdnf

33 nding phenylalanines 75 and 155 in the human dopamine transporter are the primary determinants of maz

34 We identify the dopamine transporter as a master regulator of dopamine s

35 ch as presynaptic dopamine autoreceptors and dopamine transporters-as well as heterosynaptic mechanis

36 tal structure of the Drosophila melanogaster dopamine transporter at 3.0 A resolution bound to the tr

37 Upregulation of dopamine transporter availability during long-term treat

38 methylphenidate treatment increased striatal dopamine transporter availability in ADHD (caudate, puta

39 he discrepancies in the literature regarding dopamine transporter availability in ADHD participants (

40 ability prior to treatment but showed higher dopamine transporter availability in ADHD participants t

41 dopamine transporter radioligand) to measure dopamine transporter availability in the brains of 18 ne

42 ipants revealed no significant difference in dopamine transporter availability prior to treatment but

43 Dopamine transporter availability was quantified as non-

44 icantly correlated with juvenile measures of dopamine transporter availability, whereas no significan

45 ed significant group differences in striatal dopamine transporter binding (all age ranges in caudate

46 kinson's disease (n=15) had reduced striatal dopamine transporter binding and (18)F-FDOPA uptake, com

47 hoton emission CT (SPECT) to assess striatal dopamine transporter binding and MRI for volumetric anal

48 Furthermore, these mice showed reduced dopamine transporter binding and slower dopamine clearan

49 Patients with normal dopamine transporter binding did not improve.

50 ion of the ventral nigral tier with striatal dopamine transporter binding in pre-commissural and post

51 of patients into groups with normal and low dopamine transporter binding in the caudate.

52 )F-FDOPA uptake comparable with controls and dopamine transporter binding lower than in controls.

53 Patients with low caudate dopamine transporter binding showed improvement in respo

54 se (n=25) had greater (18)F-FDOPA uptake and dopamine transporter binding than did individuals with s

55 ne, 51.6% of 397 patients had normal caudate dopamine transporter binding, 26.0% had unilateral cauda

56 Imaging revealed a robust increase in dopamine transporter binding, an effect confirmed by por

57 Striatal dopamine transporter binding, VMAT2 binding, (18)F-FDOPA

58 In a neuroimaging substudy, striatal dopamine-transporter binding was assessed by SPECT.

59 riatum and central thalamus before and after dopamine transporter blockade with dextroamphetamine.

60 al subregions, whereas both fluoxetine and a dopamine transporter blocker depress reuptake in striatu

61 Application of the dopamine transporter blocker, methylphenidate, significa

62 on a clinical trial using amantadine, a weak dopamine transporter blocker.

63 t of antipsychotic drugs and predicting that dopamine transporter blockers may be an adjunct treatmen

64 Blockade of the dopamine transporter, but not the norepinephrine transpo

65 The dopamine transporter carries an endogenous binding site

66 lar monoamine transporter type 2 (DTBZ), and dopamine transporter (CFT) within 2 months after nigrost

67 Together, the data suggest that the dopamine transporter contributes to homeostatic sleep-wa

68 h genes in postmitotic mDA neurons using the dopamine transporter-cre mouse.

69 PDM blocked the endogenous basal hDAT (human dopamine transporter) current in voltage-clamped (-60 mV

70 l lines expressing the human plasma membrane dopamine transporter (DAT) and human VMAT ortholog, VMAT

71 on methylphenidate (MPH), which binds to the dopamine transporter (DAT) and the norepinephrine transp

72 tic polymorphisms reducing expression of the dopamine transporter (DAT) are associated with some cond

73 cle deacidification also requires functional dopamine transporter (DAT) at the plasma membrane.

74 acities, dopamine D(2/3) receptor (D2/3R) or dopamine transporter (DAT) availabilities, or synaptic d

75 DG PET provides complementary information on dopamine transporter (DAT) availability and overall brai

76 lucinations, and fluctuations) with striatal dopamine transporter (DAT) availability as assessed with

77 ormed a comparative analysis of the striatal dopamine transporter (DAT) availability between the two

78 We also measured dopamine transporter (DAT) availability in three subject

79 Dopamine transporter (DAT) availability was assessed wit

80 The dopamine transporter (DAT) belongs to the family of neur

81 The dopamine transporter (DAT) belongs to the neurotransmitt

82 g pregnancy, we imaged striatal and midbrain dopamine transporter (DAT) binding by positron emission

83 reduces Parkinsonian symptoms and increases dopamine transporter (DAT) binding in several animal mod

84 tudy was to examine the relationship between dopamine transporter (DAT) binding in the striatum in in

85 T) SPECT can visualize and quantify striatal dopamine transporter (DAT) binding in vivo.

86 related human alpha-synuclein A53T mutant or dopamine transporter (DAT) blockers also differentially

87 Folding-defective mutants of the human dopamine transporter (DAT) cause a syndrome of infantile

88 The dopamine transporter (DAT) clears the extracellular dopa

89 The sodium-coupled dopamine transporter (DAT) controls dopamine homeostasis

90 Dopamine transporter (DAT) controls dopamine neurotransm

91 The dopamine transporter (DAT) controls the spatial and temp

92 ined cfos imaging and retrograde labeling in dopamine transporter (DAT) Cre mice revealed that a larg

93 yrosine hydroxylase (TH) immunohistology and dopamine transporter (DAT) density with DAT immunohistol

94 puted tomography (SPECT), to assess striatal dopamine transporter (DAT) density.

95 que dopamine uptake inhibitor that binds the dopamine transporter (DAT) differently than cocaine and

96 ion of synaptic dopamine (DA) content by the dopamine transporter (DAT) ensures the phasic nature of

97 ple aspects of dopamine signaling, including dopamine transporter (DAT) expression and dopamine reupt

98 in an enriched condition (EC) have decreased dopamine transporter (DAT) function and expression in me

99 cit are unknown, but may include the reduced dopamine transporter (DAT) functioning reported in BD pa

100 The dopamine transporter (DAT) functions as a key regulator

101 kinase, play key roles in the regulation of dopamine transporter (DAT) functions.

102 rder caused by loss-of-function mutations in dopamine transporter (DAT) gene, leading to severe neuro

103 The human dopamine transporter (DAT) has a tetrahedral Zn(2+)-bind

104 at protein-mediated direct inhibition of the dopamine transporter (DAT) has been implicated as a medi

105 The dopamine transporter (DAT) has been implicated in a vari

106 ed transport reversal at the closely related dopamine transporter (DAT) has been shown previously to

107 Dopamine transporter (DAT) has been shown to accumulate

108 itory activity on and selectivity toward the dopamine transporter (DAT) has previously led to the pro

109 of smell identification testing followed by dopamine transporter (DAT) imaging can accurately and ef

110 To determine the usefulness of dopamine transporter (DAT) imaging to identify idiopathi

111 e top candidate biomarker were measured, and dopamine transporter (DAT) imaging was performed, to eva

112 motor and non-motor scales, 123-I Ioflupane dopamine transporter (DAT) imaging, and biological varia

113 stinct striatal dopamine abnormalities using dopamine transporter (DaT) imaging.

114 ere used to measure cocaine occupancy of the dopamine transporter (DAT) in nonhuman primates.

115 de antisera against M5R and the plasmalemmal dopamine transporter (DAT) in single sections through th

116 ligand for the in vivo quantification of the dopamine transporter (DAT) in the striatum and substanti

117 effects on [DA]o at high and low doses, one dopamine transporter (DAT) independent and one DAT depen

118 The dopamine transporter (DAT) inhibitor, nomifensine, simil

119 Atypical dopamine transporter (DAT) inhibitors have shown therape

120 ogy are discussed.SIGNIFICANCE STATEMENT The dopamine transporter (DAT) is a key regulator of dopamin

121 The dopamine transporter (DAT) is a major regulator of synap

122 The dopamine transporter (DAT) is a presynaptic membrane pro

123 The dopamine transporter (DAT) is an important regulator of

124 The dopamine transporter (DAT) is responsible for sequestrat

125 The dopamine transporter (DAT) is responsible for terminatin

126 The dopamine transporter (DAT) is the key regulator of the d

127 The dopamine transporter (DAT) is the primary molecular targ

128 Although the dopamine transporter (DAT) is the primary site of action

129 Dopamine transporter (DAT) is the target of cocaine and

130 oltammetry in rats, as well as wild-type and dopamine transporter (DAT) knock-out mice, we demonstrat

131 at MPH self-administration in rats increases dopamine transporter (DAT) levels and enhances the poten

132 te of uptake (Vmax), and membrane-associated dopamine transporter (DAT) levels were reduced, and the

133 mission and mania, whilst increased striatal dopamine transporter (DAT) levels would lead to reduced

134 ures reminiscent of ADHD, including elevated dopamine transporter (DAT) levels, hyperactivity, workin

135 asis on SPECT performed with the presynaptic dopamine transporter (DAT) ligand (123)I-FP-CIT.

136 fied levels of tyrosine hydroxylase (TH) and dopamine transporter (DAT) mRNA using quantitative polym

137 rast, GHR ablation in cells that express the dopamine transporter (DAT) or dopamine beta-hydroxylase

138 tropane ((18)F-FE-PE2I) is a newly developed dopamine transporter (DAT) PET radioligand.

139 As an approach to elucidating dopamine transporter (DAT) phosphorylation characteristi

140 As the dopamine transporter (DAT) plays a prominent role in the

141 t binds reversibly with high affinity to the dopamine transporter (DaT) protein, a marker for presyna

142 The dopamine transporter (DAT) regulates dopamine (DA) neuro

143 The dopamine transporter (DAT) regulates dopamine neurotrans

144 The dopamine transporter (DAT) reversibly transports dopamin

145 ives post translational modifications at the dopamine transporter (DAT) to increase the ability of co

146 A53T mice had increased distribution of the dopamine transporter (DAT) to the membrane that was asso

147 we link tolerance to cocaine effects at the dopamine transporter (DAT) with aberrant cocaine-taking

148 It is targeting the dopamine transporter (DAT) with moderate selectivity, th

149 ly determined by its capacity to inhibit the dopamine transporter (DAT), and emerging evidence sugges

150 orter (ClC-ec1), leucine transporter (LeuT), dopamine transporter (DAT), and serotonin transporter (S

151 tors (DRD1, DRD2, DRD3, DRD4, and DRD5), the dopamine transporter (DAT), and vesicular transporters (

152 Tracers for dopamine transporter (DAT), aromatic amino acid decarbox

153 pamine transients are slower, independent of dopamine transporter (DAT), increasing the lifetime of e

154 can be identified by their expression of the dopamine transporter (DAT), provide the earliest opportu

155 In the human dopamine transporter (DAT), the corresponding residues a

156 ch as amphetamine and methamphetamine is the dopamine transporter (DAT), the major regulator of extra

157 on extracellular DA-level regulation by the dopamine transporter (DAT), the membrane expression and

158 ic re-uptake of dopamine is dependent on the dopamine transporter (DAT), which is regulated by its di

159 recessive loss-of-function mutations in the dopamine transporter (DAT), which often affects transpor

160 ction, and reduces cocaine inhibition of the dopamine transporter (DAT), which results in tolerance.

161 In dopamine transporter (DAT)-Cre mice, overexpression of C

162 ryogenesis (EIIa-Cre) or only in DA neurons (dopamine transporter (DAT)-Cre), we developed constituti

163 In contrast to the classical dopamine transporter (DAT)-dependent enhancement of the

164 riments against tyrosine hydroxylase (TH) or dopamine transporter (DAT).

165 fflux than [(3)H]dopamine uptake through the dopamine transporter (DAT).

166 imulant methamphetamine, a substrate for the dopamine transporter (DAT).

167 s of cocaine at its main site of action, the dopamine transporter (DAT).

168 rd relevant mechanistic targets, such as the dopamine transporter (DAT).

169 s, vesicular release of DA is cleared by the dopamine transporter (DAT).

170 stimulate endocytosis of the plasma membrane dopamine transporter (DAT).

171 Striatal CYAM overlapped with the dopamine transporter (DAT).

172 the dopaminergic signal is regulated by the dopamine transporter (DAT).

173 the dopaminergic signal are regulated by the dopamine transporter (DAT).

174 morphism of the gene (DAT1, SLC6A3) encoding dopamine transporter (DAT).

175 enting tolerance to cocaine's effects at the dopamine transporter (DAT).

176 hat demonstrates a novel binding mode at the dopamine transporter (DAT).

177 ed a quantitative autoradiographic survey of dopamine transporter (DAT; [(3)H]mazindol), D1 receptor

178 mulation, and (2) DA reuptake occurs through dopamine transporters (DAT) in a manner consistent with

179 l data, APOE status, and biomarkers (CSF and dopamine transporter [DAT] imaging results).

180 ht to result from cocaine's ability to block dopamine transporters (DATs).

181 al structures of the Drosophila melanogaster dopamine transporter (dDAT) bound to its substrate dopam

182 Dopamine Transporter Deficiency Syndrome (DTDS) is a rar

183 amine transporter gene, including hereditary dopamine transporter deficiency syndrome (DTDS).

184 expands the clinical phenotypic continuum of dopamine transporter deficiency syndrome and indicates t

185 Dopamine transporter deficiency syndrome due to SLC6A3 m

186 ncluded three adolescent males with atypical dopamine transporter deficiency syndrome of juvenile ons

187 Dopamine transporter deficiency syndrome remains under-r

188 nder-recognized and our data highlights that dopamine transporter deficiency syndrome should be consi

189 a neurotransmitter profile characteristic of dopamine transporter deficiency syndrome were recruited

190 ave identified a new cohort of patients with dopamine transporter deficiency syndrome, including, mos

191 w patients from five unrelated families with dopamine transporter deficiency syndrome.

192 In vitro studies of mutant dopamine transporter demonstrated multifaceted loss of d

193 n with serum urate level to predict striatal dopamine transporter density among all PPMI participants

194 individuals with physiological reductions in dopamine transporter density consistent with prodromal P

195 the PPMI sample, on progression of striatal dopamine transporter density over the 22-month follow-up

196 Similarly, lower dopamine transporter density was observed in the ventral

197 son's disease and correlated the findings to dopamine transporter density, measured by (123)I-FP-CIT

198 Independent of striatal dopamine transporter density, similar effects on brain a

199 ation between nigral pigmentation and nigral dopamine transporter density.

200 chostimulants was negatively correlated with dopamine transporter density; density was higher in pati

201 In contrast to NET, the dopamine transporter displayed markedly less constitutiv

202 ydroxylase (pTH-Ser40) levels in the VTA and dopamine transporter expression in the NAc.

203 idence of decreased tyrosine hydroxylase and dopamine transporter expression in the old rats support

204 lular side toward the unoccupied Na2 site of dopamine transporter following the release of the Na2-bo

205 Dopamine transporter function is regulated by protein ki

206 ransporter demonstrated multifaceted loss of dopamine transporter function.

207 egenerative diseases that involve changes in dopamine transporter function.

208 In the dog, the dopamine transporter gene (DAT) contains a 38-base pair

209 n which Cre- recombinase expression is under dopamine transporter gene (DAT) promoter control to abla

210 Functional polymorphisms in the dopamine transporter gene (DAT1 or SLC6A3) modulate resp

211 Genetic polymorphisms of the dopamine transporter gene (DAT1) and perinatal complicat

212 ble number tandem repeat polymorphism in the dopamine transporter gene (DAT1/SLC6A3), which has been

213 unctional tandem repeat polymorphisms of the dopamine transporter gene (DAT1; SLC6A3), which are argu

214 We show that disruption of the dopamine transporter gene lengthens the period of ultrad

215 ditions have been linked to mutations in the dopamine transporter gene, including hereditary dopamine

216 opamine receptors, tyrosine hydroxylase, and dopamine transporter genes in the zebrafish brain.

217 face transporter, loss of post-translational dopamine transporter glycosylation and failure of amphet

218 ms; P = 0.002) with no change in the normal dopamine transporter group (P = 0.50).

219 The low dopamine transporter group also improved on self-reporte

220 eaction time results supported this: the low dopamine transporter group improved (median change -19 m

221 The human dopamine transporter (hDAT) regulates the level of the n

222 imental verifications in both LeuT and human dopamine transporter (hDAT), we apply the novel method t

223 nsmission including dopamine uptake by human dopamine transporter (hDAT).

224 int mutations in the gene encoding the human dopamine transporter (hDAT, SLC6A3) cause a syndrome of

225 line and assessed annually, including serial dopamine transporter imaging (DAT-SPECT) and ICD assessm

226 d MRI and 29/36 and 25/30, respectively, had dopamine transporter imaging by (123)I-ioflupane single-

227 evelopments in diagnosis, such as the use of dopamine transporter imaging for drug-induced parkinsoni

228 Dopamine transporter imaging was abnormal in all parkins

229 Brain perfusion and dopamine transporter imaging was analyzed, including dem

230 cluded cerebrospinal fluid (CSF) markers and dopamine transporter imaging.

231 disease who had undergone both diffusion and dopamine transporter imaging.

232 were processed for tyrosine hydroxylase and dopamine transporter immunohistochemistry.

233 that cocaine self-administration leaves the dopamine transporter in a "primed" state, which allows f

234 clinical decision making by visualising the dopamine transporter in parkinsonian cases.

235 While (123)I-FP-CIT binds primarily to dopamine transporters in the striatum, its binding in th

236 important role in regulating the function of dopamine transporters in the striatum.SIGNIFICANCE STATE

237 molecular dynamics trajectories of the human dopamine transporter, in which multiple spontaneous Na(+

238 nistration in rats produced tolerance to the dopamine transporter-inhibiting effects of cocaine in th

239 Strikingly, dopamine transporter inhibition completely restored alco

240 Systemic administration of the dopamine transporter inhibitor nomifensine increases res

241 rupt D4 receptor activation initiated by the dopamine transporter inhibitor, GBR12935.

242 etamine (AMPH), cocaine, and other addictive dopamine-transporter inhibitors (DAT-Is) supports transi

243 outcomes, supporting the hypothesis that the dopamine transporter is a main target of antipsychotic d

244 The dopamine transporter is a neuronal protein that drives t

245 Although the overall structure of the dopamine transporter is similar to that of its prokaryot

246 hetamine enters dopamine neurons through the dopamine transporter, it stimulates endocytosis of an ex

247 me amphetamine-mediated behaviors persist in dopamine transporter knock-out animals, suggesting the e

248 s the spontaneous hyperactivity exhibited by dopamine transporter knock-out mice.

249 ABA was also tested in dopamine transporter knockdown mice and wild-type litter

250 ximately 80% decrease in brain serotonin and dopamine transporter knockout (DAT-KO) mice showing a fi

251 The GluN1-Knockdown (GluN1KD) and Dopamine Transporter Knockout (DATKO) mice are models of

252 We investigate whether measuring dopamine transporter levels using 123I-ioflupane single-

253 ar depression imaging studies show increased dopamine transporter levels, but changes in other aspect

254 were only seen in patients with low caudate dopamine transporter levels.

255 nsients, suggesting that the activity of the dopamine transporter limits the detection of these event

256 orted that RGS12-null mice exhibit increased dopamine transporter-mediated dopamine (DA) uptake in th

257 in the NAc, whereas tyrosine hydroxylase and dopamine transporter mRNA levels and tissue dopamine con

258 Dopamine transporter mutants also showed diminished dopa

259 sally present, and more severely impacted in dopamine transporter mutants causing infantile-onset rat

260 profiling of rationally chosen serotonin and dopamine transporter mutants with respect to a series of

261 ically reduced in early stage, untreated and dopamine transporter neuroimaging-supported Parkinson's

262 al analyses, suggesting that upregulation of dopamine transporter occurs as part of an early patholog

263 valuated by determining the effect of mutant dopamine transporter on dopamine uptake, protein express

264 n, including K(+)-gated excitability and the dopamine transporter, particularly in the dorsal striatu

265 elanin-sensitive MRI and the highly specific dopamine transporter PET radioligand, 11C-PE2I, to asses

266 he human serotonin transporter Tyr175 versus dopamine transporter Phe155 is found to be a strong tool

267 rol of the tyrosine hydroxylase, but not the dopamine transporter, promoter exhibit dramatic non-DA c

268 ar dopamine, striatal whole-tissue dopamine, dopamine transporter protein, dopamine uptake, or striat

269 measurement of the binding potential of the dopamine transporter radioligand (123)I-ioflupane in mou

270 e/xylazine anesthesia) was examined with the dopamine transporter radioligand (18)F-FE-PE2I (94 MBq)

271 tron emission tomography and [(11)C]cocaine (dopamine transporter radioligand) to measure dopamine tr

272 d that the pharmacological inhibition of the dopamine transporter rescued antipsychotic drug treatmen

273 arkinsonism had reduced dopamine storage and dopamine transporter reuptake.

274 ding the molecular determinants of serotonin/dopamine transporter selectivity and for the development

275 nes and barbiturates), and interactions with dopamine transporter, serotonin transporter, and vesicul

276 isms in the genes encoding the serotonin and dopamine transporters (SERT: 5HTTLPR plus rs25531; DAT1

277 The dopamine transporter shapes dopaminergic neurotransmissi

278 ss was smaller than the decrease in striatal dopamine transporter signal measured by dopamine transpo

279 (123)I-FP-CIT scan, the mean total striatal dopamine transporter signal was decreased by 45% and the

280 atal dopamine transporter signal measured by dopamine transporter single photon emission computed tom

281 d loss of dopaminergic neurons assessed with dopamine transporter single photon emission computerized

282 Dopamine transporter single-photon emission computed tom

283 rend was found for the carriers allele 9R of dopamine transporter SLC6A3 40 bp variable tandem repeat

284 In mice with a dopamine transporter (Slc6a3)-driven conditional heteroz

285 Taken together, the dopamine transporter structure reveals the molecular bas

286 sponsive FFN probe, FFN102, which as a polar dopamine transporter substrate selectively labels dopami

287 tions regulated RNA abundance of Slc6a3, the dopamine transporter, suggesting a novel genetic link fo

288 zation, insolubility and complexing with the dopamine transporter, suggesting a physiological mechani

289 nding residue found in the noradrenaline and dopamine transporters, switched the SEC24 isoform prefer

290 ethamphetamine (METH) is a substrate for the dopamine transporter that increases extracellular dopami

291 methylphenidate (Ritalin), which blocks the dopamine transporter, thereby increasing extracellular d

292 receptors, an increased translocation of the dopamine transporter to the plasma membrane and a corres

293 SPECT) with technetium 99m ((99m)Tc) tropane dopamine transporter (TRODAT)-1 were performed for furth

294 ed high levels of DOPA decarboxylase and the dopamine transporter, two markers expressed by fully mat

295 oups also had reduced striatal levels of the dopamine transporter, tyrosine hydroxylase, and the dopa

296 ptor (MOR), preproenkephalin (PENK), and the dopamine transporter was evaluated in the hypothalamus a

297 nal consequences of missense variants on the dopamine transporter were evaluated by determining the e

298 elease evoked by amphetamine, which reverses dopamine transporters, were also unaffected.

299 Methylphenidate blocks the dopamine transporter, which increases extracellular dopa

300 is essential for dopamine synthesis, and the dopamine transporter, which is required for dopamine upt